Future of Drug Development in Multiple Myeloma: An IMS-FDA Joint Symposium

November 8 - 9, 2022 - Online and in person at the The Bethesdan Hotel, Bethesda Maryland

The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and multiple myeloma remains a difficult disease to treat, so the need for new therapies remains.  Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to facilitate future drug development and improve patient outcomes.

On November 8-9, 2022, the IMS will host a joint symposium with the FDA, to provide a forum for open discussion among academia, industry and regulatory agencies about clinical drug development in multiple myeloma. This workshop will discuss trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population.

Preliminary Program 

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events